OXIS International, Inc. (OTCMKTS:OXIS) is holding gains today after a recent important announcement. The stock is up 6% in afternoon trading and the volume has been strong especially in the morning. OXIS is riding news that four patients have been enrolled in the company’s Phase 2 clinical trial of its promising cancer therapy, OXS-1550. The company has high hopes for the testing.

“The product performed well in Phase 1 studies of blood cancers and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors,” OXIS’s Executive Chairman said.

OXIS International, Inc. (OTCMKTS:OXIS) frames itself as a company that, through its wholly owned subsidiary of Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs focused on the treatment of cancer.

Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer; OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesion; and OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors.

Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs.

OXIS’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.”

Find out when $OXIS stock reaches critical levels. Subscribe to FinanceRegistrar.com Right Now by entering your Email in the box below.

This new test and subsequent are built on the hope that this drug will takeoff as a less invasive treatment option.

The Phase 2 clinical trial is being conducted with Oxis’ partner, the University of Minnesota’s Masonic Cancer Center. Earlier this year, researchers at the University of Minnesota completed a Phase 1 trial of OXS-1550 to determine the safe and effective dose of the drug. The Phase 2 portion of the trial began in April and a total of 12 patients are expected to participate. Results of the Phase 2 trial are expected to be released in the first quarter of 2018.

OXS-1550 uses a proprietary immunoconjugate platform technology as a treatment for leukemia and other blood-born cancers. What sets OXS-1550 (DT2219ARL) apart from other treatments, such as chemotherapy, is that it is designed to specifically target and kill cancer cells while minimizing damage to normal tissues.

Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, helped develop OXS-1550. “The initiation of Phase 2 patient treatment is a key opportunity to demonstrate the effectiveness of this promising cancer therapy,” Dr. Vallera said

OXIS International, Inc. (OTCMKTS:OXIS) is carrying a $5.64M market cap with 144.71M shares out. The company is in a very important moment and gathering deserved interest across the OTC. We are watching the company carefully to see if they can maintain this upward track. For additional coverage on shares of $OXIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $OXIS, either long or short, and we have not been compensated for this article.